Cardiovascular Benefits of Dietary Melatonin: A Myth or a Reality?
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The role of the diet as well as the impact of the dietary habits on human health and disease is well established. Apart from its sleep regulatory effect, the indoleamine melatonin is a well-established antioxidant molecule with multiple health benefits. Convincing evidence supports the presence of melatonin in plants and foods with the intake of such foods affecting circulating melatonin levels in humans. While numerous actions of both endogenous melatonin and melatonin supplementation are well described, little is known about the influence of the dietary melatonin intake on human health. In the present review, evidence for the cardiovascular health benefits of melatonin supplementation and dietary melatonin is discussed. Current knowledge on the biological significance as well as the underlying physiological mechanism of action of the dietary melatonin is also summarized. Whether dietary melatonin constitutes an alternative preventive treatment for cardiovascular disease is addressed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet
Estruch, R., Ros, E., Salas-Salvadó, J., Covas, M.-I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1200303 · Cited by 4,257
RetractedAune, D., Giovannucci, E., Boffetta, P., Fadnes, L. T., Keum, N., Norat, T., Greenwood, D. C., Riboli, E., Vatten, L. J., & Tonstad, S. (2017) · International Journal of Epidemiology · doi:10.1093/ije/dyw319 · Cited by 2,419 · cited 7×
“However, a better understanding of the mechanisms involved in this effect are required before it can be considered as an adjuvant for effective preventive and curative therapy in CVDs.”
BackgroundInfluentialMelatonin: Nature’s most versatile biological signal?
Pandi‐Perumal, S. R., Srinivasan, V., Maestroni, G. J. M., Cardinali, D. P., Poeggeler, B., & Hardeland, R. (2006) · The FEBS Journal · doi:10.1111/j.1742-4658.2006.05322.x · Cited by 875 · cited 2×
“As indicated above, melatonin exhibits its physiological functions through its antioxidant, anti-inflammatory, immune-modulatory and vasomotor activities (Pandi-Perumal et al., 2006).”
BackgroundMelatonin—A pleiotropic, orchestrating regulator molecule
Hardeland, R., Cardinali, D. P., Srinivasan, V., Spence, D. W., Brown, G. M., & Pandi-Perumal, S. R. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.12.004 · Cited by 843
Afshin, A., Micha, R., Khatibzadeh, S., & Mozaffarian, D. (2014) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.076901 · Cited by 509 · cited 1×
“Today, the health benefits of the Mediterranean diet are well established (Estruch et al., 2013; Afshin et al., 2014).”
BackgroundDaily nighttime melatonin reduces blood pressure in male patients with essential hypertension
Scheer, F. A. J. L., Van Montfrans, G. A., van Someren, E. J. W., Mairuhu, G., & Buijs, R. M. (2004) · Hypertension · doi:10.1161/01.hyp.0000113293.15186.3b · Cited by 451 · cited 1×
“In human studies, night time melatonin administration (2– 5 mg/day for 3–4 weeks) reduces BP values of hypertensive men (Scheer et al., 2004; Grossman et al., 2006) or women (Cagnacci et al., 2005) as well as normotensive women (Cagnacci et al., 2005).”
BackgroundMelatonin secretion and the incidence of type 2 diabetes
McMullan, C. J., Schernhammer, E. S., Rimm, E. B., Hu, F. B., & Forman, J. P. (2013) · JAMA · doi:10.1001/jama.2013.2710 · Cited by 369 · cited 2×
“…hypertension (Kozirog et al., 2011; Dominguez-Rodriguez et al., 2014), heart failure (Girotti et al., 2003; Dzida et al., 2013; Kimak et al., 2014; Dominguez-Rodriguez et al., 2016) and cardiovascular risk conditions such as diabetes (McMullan et al., 2013) and obesity (Mantele et al., 2012).”
BackgroundDietary Sources and Bioactivities of Melatonin
Meng, X., Li, Y., Li, S., Zhou, Y., Gan, R.-Y., Xu, D.-P., & Li, H.-B. (2017) · Nutrients · doi:10.3390/nu9040367 · Cited by 362
Metabolism of melatonin by human cytochromes p450
Ma, X., Idle, J. R., Krausz, K. W., & Gonzalez, F. J. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002410 · Cited by 319 · cited 3×
“Melatonin may also be transformed to a less extend by CYP2C19 and CYP1A2 mediated O-demethylation in N-acetylserotonin (N-acetyl-5-hydroxytryptamine) or by deacetylation to 5-methoxytryptamine which can be reconverted to melatonin (Ma et al., 2005).”
BackgroundKoziróg, M., Poliwczak, A. R., Duchnowicz, P., Koter-Michalak, M., Sikora, J., & Broncel, M. (2011) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2010.00835.x · Cited by 299 · cited 4×
“…supplementation (5 mg/day, 2 h before bedtime) for 2 months reduces the systolic and diastolic BP, lowdensity lipoprotein cholesterol (LDL-C), thiobarbituric acid reactive substrates (TBARS, a marker of oxidative stress) and increases antioxidant defense (catalase activity) (Kozirog et al., 2011).”
BackgroundInfluential
Cited by
Melatonin’s Impact on Antioxidative and Anti-Inflammatory Reprogramming in Homeostasis and Disease
Chitimus, D. M., Popescu, M. R., Voiculescu, S. E., Panaitescu, A. M., Pavel, B., Zagrean, L., & Zagrean, A.-M. (2020) · Biomolecules · doi:10.3390/biom10091211 · Cited by 354
Morris, G., Puri, B. K., Bortolasci, C. C., Carvalho, A., Berk, M., Walder, K., Moreira, E. G., & Maes, M. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.037 · Cited by 84
Lower Plasma Melatonin Levels Predict Worse Long-Term Survival in Pulmonary Arterial Hypertension
Cai, Z., Klein, T., Geenen, L. W., Tu, L., Tian, S., van den Bosch, A. E., de Rijke, Y. B., Reiss, I. K. M., Boersma, E., Duncker, D. J., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051248 · Cited by 17
“Furthermore, several studies show cardiovascular protective effects of exogenous melatonin in both humans and animal models [5–7, 42, 43 ], suggesting that higher”
Background
Metadata
- Authors
- Jiki, Z., Lecour, S., & Nduhirabandi, F.
- Venue
- Frontiers in Physiology
- Publisher
- Frontiers Media SA
- Published
- 2018-05-17
- Volume
- 9
- Pages
- 528-528
- ISSN
- 1664-042X (ISSN-L)
- OpenAlex
- W2800681296
- Cited by
- 88
- References
- 17
- FWCI
- 4.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.